NEW YORK – Avatamed, a Singapore-based precision medicine company, has completed a $1 million seed funding round led by Future Leading Bio Funds alongside other unnamed investors.
Avatamed said it will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.